Document is current
Any future updates will be listed below
-
Authors
Deng, Wei Q. https://orcid.org/0000-0003-4212-2607
Belisario, Kyla https://orcid.org/0000-0001-5403-9531
Munafò, Marcus R. https://orcid.org/0000-0002-4049-993X
MacKillop, James https://orcid.org/0000-0003-4118-9500
-
Funding
Funding for this research was provided by:
Wellcome Trust (217065/Z/19/Z, 217065/Z/19/Z, 217065/Z/19/Z, 217065/Z/19/Z)
Peter Boris Centre for Addictions Research
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (CRC-2020-00179)
- License Information
-
More Information
Article History
Received: 13 January 2024
Revised: 14 August 2024
Accepted: 16 August 2024
First Online: 24 August 2024
Competing interests
: JM is a principal in Beam Diagnostics, Inc. and a consultant to Clairvoyant Therapeutics, Inc. No other authors have disclosures.
: Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. All PATH CANN participants underwent informed consent, and the registry was approved by the Hamilton Integrated Review Ethics Board (#1074).
